Business Context and Reporting Period
Company: Dogwood Therapeutics, Inc. (formerly Virios Therapeutics, Inc.)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2024
Business Overview: Dogwood is a pre-revenue, development-stage biopharmaceutical company focused on two therapeutic pillars: (1) Nav1.7 modulation for pain disorders via its lead candidate Halneuron (tetrodotoxin-based) for chemotherapy-induced neuropathic pain (CINP); and (2) combination antiviral therapies (IMC-1 and IMC-2) targeting reactivated herpes viruses for fibromyalgia (FM) and Long-COVID (LC).
Recent Corporate Action: On October 7, 2024, the Company completed a business combination with Pharmagesic (Holdings) Inc., acquiring its assets and changing its name to Dogwood Therapeutics, Inc. A 25-for-1 reverse stock split was also effected on this date.
Key Financial Metrics
| Metric | 2024 | 2023 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(12,349,724) | $(5,296,015) |
| Operating Expenses | $12,227,248 | $5,446,919 |
| Research & Development (R&D) | $3,530,913 | $1,728,078 |
| General & Administrative (G&A) | $8,696,335 | $3,718,841 |
| Cash and Cash Equivalents (Dec 31, 2024) | $14,847,949 | $3,316,946 |
| Accumulated Deficit (Dec 31, 2024) | $(73,818,946) | $(61,469,222) |
| Debt (Related Party Loan, net) | $15,381,077 | $0 |
Note: The 2024 G&A expenses include approximately $4.9 million in non-recurring transaction costs related to the business combination.
Material Changes vs. Prior Period
- Acquisition Impact: The combination with Pharmagesic resulted in the recognition of $69.5 million in In-Process Research and Development (IPR&D) intangible assets and $12.5 million in goodwill. This significantly altered the balance sheet structure compared to 2023.
- Expense Growth: Total operating expenses increased by 124% year-over-year, driven primarily by the $4.9 million in transaction costs and increased R&D spending for the initiation of the HALT-CINP-203 Phase 2b trial.
- Financing Activity: The Company secured a $19.5 million related-party loan in October 2024 (partially disbursed in 2024) and raised $1.38 million net from a public offering in May 2024. Net cash provided by financing activities was $16.7 million in 2024 compared to $1.2 million in 2023.
- Cash Position: Cash balances increased by $11.7 million, largely due to cash acquired in the business combination ($3.8 million) and financing proceeds.
Guidance, Outlook, Risks, and Unusual Items
Outlook and Guidance
Management anticipates that cash on hand ($14.8 million as of Dec 31, 2024), combined with subsequent loan proceeds ($3 million received Feb 2025) and a March 2025 registered direct offering ($4.25 million net), will fund operations through the first quarter of 2026. The Company expects to incur significant additional operating losses as it advances clinical trials.
Key Risks and Contingencies
- Going Concern: The independent auditor has issued an explanatory paragraph regarding substantial doubt about the Company's ability to continue as a going concern without additional capital. The Company has an accumulated deficit of $73.8 million and no commercial revenue.
- Nasdaq Compliance: The Company received notice in November 2024 that its stockholders' equity fell below the $2.5 million minimum requirement. A compliance plan was submitted, and the Company was granted until May 14, 2025, to regain compliance. Failure to do so could result in delisting.
- Clinical Development Risks:
- Halneuron: Phase 2b trial (HALT-CINP-203) commenced in Q1 2025. Interim data is expected in Q4 2025.
- IMC-1 (Fibromyalgia): The Phase 2b FORTRESS study did not achieve statistical significance on the primary endpoint overall, though post-hoc analysis showed significance in "New" patients enrolled later in the trial. The Company is seeking partners for Phase 3.
- IMC-2 (Long-COVID): A recent Phase 2 study showed clinically meaningful improvements in fatigue but was not statistically significant due to small sample size (44 patients).
- Debt Conversion: In March 2025, the Company entered into an agreement to exchange the outstanding principal and accrued interest of the related-party loan (approx. $19.9 million) for Series A-1 Non-Voting Convertible Preferred Stock.
Investor Verification Checklist
- Liquidity Runway: Verify the closing of the March 2025 offering and the sufficiency of funds to reach the Q1 2026 milestone without further dilution.
- Nasdaq Status: Monitor the Company's progress in meeting the $2.5 million stockholders' equity requirement by the May 14, 2025 deadline to avoid delisting.
- Clinical Data Readouts: Track the interim analysis of the HALT-CINP-203 trial (expected Q4 2025) and the design of the Phase 3 program for IMC-1.
- Debt-to-Equity Conversion: Confirm the final terms and dilution impact of the March 2025 debt exchange into Series A-1 Preferred Stock.
- Transaction Costs: Review the $4.9 million in non-recurring transaction costs expensed in 2024 to understand the true underlying operational burn rate.